Prognostic significance and potential therapeutic target of VEGFR2 in hepatocellular carcinoma

Journal of Clinical Pathology

Volumn 64, Issue 4, 2011, Pages 343-348

  Huang, Jianfei ^a,b   Zhang, Xialing ^a   Tang, Qi ^a   Zhang, Feng ^a   Li, Yuhua ^a   Feng, Zhenqing ^a   Zhu, Jin ^a,c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANTONG UNIVERSITY   (China)

^c Huadong Medical Institute of Biotechniques   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A8H1; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL TIME; TUMOR DIFFERENTIATION; TUMOR VOLUME; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; RNA, MESSENGER; RNA, NEOPLASM; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; YOUNG ADULT;

EID: 79953090713     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2010.085142     Document Type: Article

References (37)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Yuen MF, Hou JL, Chutaputti A; Asia Pacific Working Party on Prevention of Hepatocellular Carcinoma. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 2009;24:346-53.
3. Baek JY, Morris SM, Campbell J, et al. TGF-beta inactivation and TGF-alpha overexpression cooperate in an in vivo mouse model to induce hepatocellular carcinoma that recapitulates molecular features of human liver cancer. Int J Cancer 2010;127:1060-71.
4. Hamilton SR, Aaltonen LA. Pathology and Genetics of Tumours of the Digestive System. World Health Organization Classification of Tumours (WHO OMS). Lyon: IARC Press, 2000:157-72.
5. Guo X, Jin Y, Qian G, et al. Sequential accumulation of the mutations in core promoter of hepatitis B virus is associated with the development of hepatocellular carcinoma in Qidong, China. J Hepatol 2008;49:718-25.
6. Jiang W, Wang XW, Unger T, et al. Cooperation of tumour-derived HBx mutants and p53-249(ser) mutant in regulating cell proliferation, anchorage-independent growth and aneuploidy in a telomerase-immortalized normal human hepatocyte-derived cell line. Int J Cancer 2010;127:1011-20.
7. Ming L, Thorgeirsson SS, Gail MH, et al. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology 2002;36:1214-20. (Pubitemid 35253438)
8. Mendizabal M, Reddy KR. Current management of hepatocellular carcinoma. Med Clin North Am 2009;93:885-900.
9. Blum HE. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol 2005;11:7391-400. (Pubitemid 43126017)
10. Lang SA, Brecht I, Moser C, et al. Dual inhibition of Raf and VEGFR2 reduces growth and vascularization of hepatocellular carcinoma in an experimental model. Langenbecks Arch Surg 2008;393:333-41.
11. Poon RT, Fan ST. Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome. Liver Transpl 2004;10:S39-45.
12. Dawe RS. Hepatocellular carcinoma. Lancet 2004;363:899.
13. Abou-Alfa GK, Huitzil-Melendez FD, O'Reilly EM, et al. Current management of advanced hepatocellular carcinoma. Gastrointest Cancer Res 2008;2:64-70.
14. Nakamura K, Zen Y, Sato Y, et al. Vascular endothelial growth factor, its receptor Flk-1, and hypoxia inducible factor-1a are involved in malignant transformation in dysplastic nodules of the liver. Hum Pathol 2007;38:1532-46. (Pubitemid 47418965)
15. Kiselyov A, Balakin KV, Tkachenko SE. VEGF/VEGFR signalling as a target for inhibiting angiogenesis. Expert Opin Investig Drugs 2007;16:83-107. (Pubitemid 44964169)
16. Benedetta Donati M, Gozdzikiewicz J. Angiogenesis and the progress of vascular and tumor biology: a tribute to Judah Folkman. Thromb Haemost 2008;99:647-50. (Pubitemid 351694216)
17. Wang H, Chen K, Niu G, et al. Site-specifically biotinylated VEGF(121) for near-infrared fluorescence imaging of tumor angiogenesis. Mol Pharm 2009;6:285-94.
18. Giannelli G, Sgarra C, Porcelli L, et al. EGFR and VEGFR as potential target for biological therapies in HCC cells. Cancer Lett 2008;262:257-64.
19. Zhu Z, Hattori K, Zhang H, et al. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia 2003;17:604-11. (Pubitemid 36395655)
20. Paz K, Zhu Z. Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. Current status and future perspective. Front Biosci 2005;10:1415-39.
21. Roth P, Hammer C, Piguet AC, et al. Effects on hepatocellular carcinoma of doxorubicin-loaded immunoliposomes designed to target the VEGFR-2. J Drug Target 2007;15:623-31. (Pubitemid 350031086)
22. Ran S, Huang X, Downes A, et al. Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy. Neoplasia 2003;5:297-307. (Pubitemid 37048607)
23. Zhao ZC, Zheng SS, Wan YL, et al. The molecular mechanism underlying angiogenesis in hepatocellular carcinoma: the imbalance activation of signaling pathways. Hepatobiliary Pancreat Dis Int 2003;2:529-36.
24. Iavarone M, Lampertico P, Iannuzzi F, et al. Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma. J Viral Hepat 2007;14:133-9. (Pubitemid 46146708)
25. Yamaguchi R, Yano H, Nakashima Y, et al. Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. Oncol Rep 2000;7:725-9.
26. Zeng W, Gouw AS, van den Heuvel MC, et al. The angiogenic makeup of human hepatocellular carcinoma does not favor vascular endothelial growth factor/angiopoietin-driven sprouting neovascularization. Hepatology 2008;48:1517-27.
27. von Marschall Z, Cramer T, Höcker M, et al. Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut 2001;48:87-96. (Pubitemid 32042647)
28. Amaoka N, Saio M, Nonaka K, et al. Expression of vascular endothelial growth factor receptors is closely related to the histological grade of hepatocellular carcinoma. Oncol Rep 2006;16:3-10.
29. Jia JB, Zhuang PY, Sun HC, et al. Protein expression profiling of vascular endothelial growth factor and its receptors identifies subclasses of hepatocellular carcinoma and predicts survival. J Cancer Res Clin Oncol 2009;135:847-54.
30. Huang J, Tan Y, Tang Q, et al. A high-affinity human/mouse cross-reactive monoclonal antibody, specific for VEGFR-2 linear and conformational epitopes. Cytotechnology 2010;62:61-71.
31. Tang Q, Liu YF, Zhu XJ, et al. Expression and prognostic significance of the alpha B-crystallin gene in human hepatocellular carcinoma. Hum Pathol 2009;40:300-5.
32. Donckier JE, Michel L, Delos M, et al. Interrelated overexpression of endothelial and inducible nitric oxide synthases, endothelin-1 and angiogenic factors in human papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2006;64:703-10. (Pubitemid 43775011)
33. Jebreel A, England J, Bedford K, et al. Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int J Exp Pathol 2007;88:271-7. (Pubitemid 47256303)
34. La Rosa S, Uccella S, Finzi G, et al. Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Hum Pathol 2003;34:18-27. (Pubitemid 36160017)
35. Gockel I, Moehler M, Frerichs K, et al. Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer. Oncol Rep 2008;20:845-50.
36. Chen H, Ye D, Xie X, et al. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecol Oncol 2004;94:630-5.
37. Yoshinaga K, Ito K, Moriya T, et al. Expression of vasohibin as a novel endothelium-derived angiogenesis inhibitor in endometrial cancer. Cancer Sci 2008;99:914-19. (Pubitemid 351997593)